MX

Grand Pharmaceutical Group LtdFRA Grand Pharmaceutical Stock Report

Last reporting period 31 Dec, 2023

Updated 13 Nov, 2024

Last price

Market cap $B

0.011

Micro

Exchange

XFRA - Deutsche Boerse AG

MX6A.F Stock Analysis

MX

Neutral

Based on Eyestock quantitative analysis, MX6A.F`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

69/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

21.7 %

Undervalued

Market cap $B

0.011

Dividend yield

7.97 %

Shares outstanding

3 527.14 B

Grand Pharmaceutical Group Ltd. engages in the development, manufacture and distribution of pharmaceutical products. The company employs 9,649 full-time employees The firm is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.

View Section: Eyestock Rating